Respiratory syncytial virus (RSV) is the leading cause of hospitalization for children under 5
years of age. We sought to engineer a viral antigen that provides greater protection than …

Respiratory syncytial virus (RSV) is the leading, global cause of serious respiratory disease
in infants and is an important cause of respiratory illness in older adults. No RSV vaccine is …

Respiratory syncytial virus (RSV) causes acute lower respiratory tract infections and is the
leading cause of infant hospitalizations. Recently, a promising vaccine antigen based on the …

Technologies that define the atomic-level structure of neutralization-sensitive epitopes on
viral surface proteins are transforming vaccinology and guiding new vaccine development …

Respiratory syncytial virus (RSV) has eluded active vaccination efforts for more than five
decades and continues to cause substantial morbidity and mortality in infants, the …

Respiratory syncytial virus (RSV), the main cause of infant bronchiolitis, remains a major
unmet vaccine need despite more than 40 years of vaccine research. Vaccine candidates …

Abstract Structure-based design of vaccines, particularly the iterative optimization used so
successfully in the structure-based design of drugs, has been a long-sought goal. We …

Highlights•RSV is an important cause of lower respiratory tract infection and disease at the
extremes of age.•The RSV fusion (F) glycoprotein is the major target for virus neutralizing …

Respiratory syncytial virus (RSV) remains a major human pathogen, infecting the majority of
infants before age two and causing re-infection throughout life. Despite decades of RSV …

The lack of a licensed vaccine for respiratory syncytial virus (RSV) can be partly attributed to
regulatory hurdles resulting from vaccine enhanced respiratory disease (ERD) subsequent …